The first drug for neurofibromatosis type 1 (NF1) is available to patients following the FDA’s approval of the AstraZeneca treatment earlier this year. Biotech startup NFlection Therapeutics is vying to be runner-up, but its founders say they can eventually win out with a drug that takes a different approach than the commercialized pill while also offering a safer and more effective way of addressing the tumors and skin bumps caused by the rare disease.

NFlection is developing its drug as a topical gel. CEO Christopher Powala says that unlike oral drugs that travel throughout the body and spark a range of… Read more »